Navigation Links
Neurochem Annual and Special Meeting of shareholders
Date:4/11/2008

Neurochem will host a live Web conference on Tuesday, April 15, 2008, at ------------------------------------------------------------------------

10:00 AM ET -----------

LAVAL, QC, April 11 /PRNewswire-FirstCall/ - Dr. Francesco Bellini, Chairman, President and Chief Executive Officer of Neurochem Inc. (NASDAQ: NRMX; TSX: NRM), as well as members of senior management, cordially invite you to attend the Company's Annual and Special Meeting of shareholders on Tuesday, April 15, 2008. The meeting will take place at 10:00 A.M. ET, in the Maxwell-Cummings Auditorium of the Michal and Renata Hornstein Pavilion of the Montreal Museum of Fine Arts, located at 1379 Sherbrooke Street West, Montreal, Quebec.

Following the Company's presentation, attendees will have the opportunity to interact with management through a question and answer period.

Live Web Cast

Neurochem's Annual and Special Meeting will be webcast live at 10:00 A.M. ET, on Tuesday, April 15, 2008. The live Web Cast (audio and visual) will be available on the Company's Web site at http://www.neurochem.com. The telephone numbers to access the audio portion of the meeting only are 514-861-0916 or 1-866-303-7746.

A replay of the Web Cast (audio and visual) will be available three hours following the conclusion of the presentation, and this until April 22, 2008. The telephone numbers to access the audio replay are 514-861-2272 or 1-800-408-3053, passcode 3257716#.

Please note that the dial-in numbers and Web Cast will not allow participants to ask questions. Please dial-in or access Neurochem's Web site approximately 15 minutes prior to the beginning of the presentation.

About Neurochem

Neurochem Inc. is a global health company focused on the research, development and commercialization of products to provide innovative health solutions to address critical unmet medical needs.

To Contact Neurochem

For additional information on Neurochem and its programs, please call the North American toll-free number 1-877-680-4500 or visit the Company's Web site at http://www.neurochem.com.

Certain statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, may constitute forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond Neurochem Inc.'s control. Such risks include but are not limited to: the impact of general economic conditions, general conditions in the pharmaceutical and/or nutraceutical industry, changes in the regulatory environment in the jurisdictions in which the Neurochem group does business, stock market volatility, fluctuations in costs, and changes to the competitive environment due to consolidation, that actual results may vary once the final and quality-controlled verification of data and analyses has been completed, as well as other risks disclosed in public filings of Neurochem Inc. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. The reader should not place undue reliance, if any, on any forward-looking statements included in this news release. These statements speak only as of the date made and Neurochem Inc. is under no obligation and disavows any intention to update or revise such statements as a result of any event, circumstances or otherwise, unless required by applicable legislation or regulation. Please see the Annual Information Form of Neurochem Inc. for further risk factors that might affect the Neurochem group and its business.

For further information, please contact:
Lise Hebert, PhD Vice President, Corporate Communications Tel: 450-680-4572 lhebert@neurochem.com


'/>"/>
SOURCE NEUROCHEM INC.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Neurochem moves eprodisate (KIACTA(TM)) drug development program forward for Amyloid A amyloidosis
2. Neurochem announces departure of two members of management team
3. Neurochem reports results for fourth quarter and fiscal year 2007 and important advances on corporate objectives
4. Neurochem to present at 2008 BIO CEO & Investor Conference - Presentation will be Web cast live
5. Neurochem appoints Mr. Gary Schmid as CEO of new nutraceutical business
6. Neurochem to present at JPMorgan Healthcare Conference
7. Neurochem announces European opinion for Eprodisate (KIACTA(TM)) for the treatment of AA amyloidosis
8. Neurochem announces eprodisate (KIACTA(TM)) receives acknowledgement of complete response and is granted Class 2 review
9. Neurochem announces departure of Dr. Philippe Calais, President, Global Business
10. Neurochem reports results for third quarter of fiscal 2007
11. With annual deaths from malaria on the rise: Scientists ask where is all the money going?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/11/2016)... PA (PRWEB) , ... December 11, 2016 , ... It’s ... nasal allergies that flare up. Tired of the sneezing, watery eyes and general discomfort ... solve this problem. , He then created a prototype of the patent-pending CLEAN AIR ...
(Date:12/10/2016)... ... December 09, 2016 , ... Even with breast cancer cited ... in recent years. This can be attributed to the improvement in breast cancer ... distributed. In response, Mediaplanet’s latest, cross-platform edition of “Breast Cancer Care” spotlights the ...
(Date:12/10/2016)... (PRWEB) , ... December 10, 2016 , ... ... presence in Harrisburg. PATS recently joined forces with other healthcare organizations to ... the State Capitol Rotunda in Harrisburg, featured a variety of speakers from around ...
(Date:12/9/2016)... MD (PRWEB) , ... December 09, 2016 , ... ... for counseling and aural rehabilitation—provided by audiologists—to remain a critical part of public ... Food and Drug Administration (FDA) announced this week that, starting immediately, ...
(Date:12/9/2016)... - Cincinnati, Ohio (PRWEB) , ... December 09, ... ... the production of miniature, folded, pharmaceutical inserts and outserts. As a means ... Device. This addition will enable Flottman to individually code professional inserts (PIs) ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... DIEGO , Dec. 9, 2016  Forge ... Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: ... targeting ,LpxC, for the treatment of bacterial infections ... has been recognized as an attractive antibacterial target ... a lack of suitable chemical starting points has ...
(Date:12/8/2016)... 2016  The global biosurgery market is expected to ... period of 2016 to 2021. The market is poised ... 18.21 billion in 2016. The market is primarily driven ... related injuries and spinal problems, increasing clearance of biosurgery ... blood loss management. In this report, the ...
(Date:12/8/2016)... Allergy Diagnostics Market: Scope and Methodology ... are used to determine the presence of allergens ... etc. in the samples by determining the presence ... report on global allergy diagnostics market, analyzes the ... report consists of an executive summary that provides ...
Breaking Medicine Technology: